Tolemy Bio Funding Powers AI-Native Platform for Predictable Cell Biology
May 14, 2026, 3:38 pm
Location: Spain, Community of Madrid, Torrejón de Ardoz
Employees: 1-10
Founded date: 2016
Tolemy Bio, an innovative biotech startup, recently raised €1.4 million in pre-seed funding. This investment propels Orbit, their AI-native software. Orbit provides a "virtual cell" intelligence layer. It empowers scientists to understand, predict, and control cellular systems. This technology is crucial for cell therapy and biomanufacturing advancements. It promises enhanced product reliability and patient access to advanced medicines. Tolemy Bio aims to revolutionize drug discovery and personalized treatments through predictive biology. The company's expansion focuses on deepening customer relationships and scaling its expert team. This funding solidifies Tolemy Bio's position at the forefront of AI-driven life sciences innovation.
Tolemy Bio, a cutting-edge biotech startup, has secured €1.4 million in pre-seed funding. This significant capital injection targets the firm’s innovative AI-native platform, Orbit. The investment round was led by Norrsken Evolve. Major participation came from Big Sur Ventures, JME Ventures, and Masia. Redbus Ventures also contributed. A consortium of angel investors joined the round. This funding fuels a critical advance in understanding cellular systems.
Orbit stands as Tolemy Bio's flagship product. It is an AI-native software platform. Its core mission: enable scientists to predict, understand, and direct cellular behavior. The platform functions as a virtual control panel for the cell. This capability far surpasses existing tools. Current software often lags behind modern experimental needs. Fragmented data plagues many laboratories. Orbit consolidates these disparate insights. It creates a unified, AI-driven workspace.
Cell therapy demands precise control. Biomanufacturing requires consistent outcomes. Current methodologies struggle here. Tolemy Bio’s Orbit provides a solution. It addresses critical gaps in product reliability. It enhances manufacturing consistency. Ultimately, it improves patient access to advanced medicines. Predictability in cell behavior is paramount. Orbit delivers this predictability.
The platform combines several key elements. It integrates experimental data. It utilizes advanced agentic AI. It builds sophisticated virtual-cell models. Together, these components make cell biology more interpretable. They make it more controllable. This level of insight transforms research. It accelerates therapeutic development.
Tolemy Bio was founded in 2024. Alex Ward and Caelan Anderson launched the venture. Their vision is clear: build tools grounded in laboratory reality. This "scientists for scientists" approach is fundamental. It ensures Orbit meets real-world needs. The platform bridges biology, AI, software, and data infrastructure. This intersection is where scientific breakthroughs occur.
The pre-seed capital has specific deployment targets. A primary goal is to scale Orbit's capabilities. This includes expanding data generation. Machine learning resources will grow. Engineering capabilities will see significant investment. The company also plans to deepen customer relationships. Early customer and partner deployments will receive support. This ensures direct feedback and continuous improvement.
Team expansion is another crucial focus. Tolemy Bio actively recruits across disciplines. Scientific talent is sought. Technical experts are in high demand. This strategic growth strengthens the company's innovative core. It ensures Orbit's continued evolution. The team's expertise drives the virtual-cell intelligence layer.
Tolemy Bio operates globally. It is officially based in Cambridge, UK. However, significant deployment and operations occur in Barcelona, Spain. This dual presence leverages diverse talent pools. It embraces a broad scientific community. This global perspective enhances market reach.
A key partnership highlights Tolemy Bio's market strategy. The company collaborated with California-based GeminiBio. This partnership led to aiMOS. aiMOS is a model-driven offering. It supports custom supplement development for GeminiBio customers. This collaboration demonstrates Orbit's real-world applicability. It shows direct value in biopharma innovation.
The impact of such technology extends broadly. It promises to revolutionize drug discovery. It will accelerate the development of personalized medicines. Advanced therapies, particularly, stand to benefit. The ability to model and direct complex cellular systems is a game-changer. This marks a new era for biopharma.
AI's role in life sciences is expanding rapidly. Investments in companies like Tolemy Bio underscore this trend. The future of medicine involves increasingly sophisticated digital tools. Precision and control define this future. Orbit positions Tolemy Bio at the forefront of this transformation. The company offers a glimpse into tomorrow's advanced biomedical research. Its success will pave the way for numerous therapeutic advancements.
Tolemy Bio, a cutting-edge biotech startup, has secured €1.4 million in pre-seed funding. This significant capital injection targets the firm’s innovative AI-native platform, Orbit. The investment round was led by Norrsken Evolve. Major participation came from Big Sur Ventures, JME Ventures, and Masia. Redbus Ventures also contributed. A consortium of angel investors joined the round. This funding fuels a critical advance in understanding cellular systems.
Orbit stands as Tolemy Bio's flagship product. It is an AI-native software platform. Its core mission: enable scientists to predict, understand, and direct cellular behavior. The platform functions as a virtual control panel for the cell. This capability far surpasses existing tools. Current software often lags behind modern experimental needs. Fragmented data plagues many laboratories. Orbit consolidates these disparate insights. It creates a unified, AI-driven workspace.
Cell therapy demands precise control. Biomanufacturing requires consistent outcomes. Current methodologies struggle here. Tolemy Bio’s Orbit provides a solution. It addresses critical gaps in product reliability. It enhances manufacturing consistency. Ultimately, it improves patient access to advanced medicines. Predictability in cell behavior is paramount. Orbit delivers this predictability.
The platform combines several key elements. It integrates experimental data. It utilizes advanced agentic AI. It builds sophisticated virtual-cell models. Together, these components make cell biology more interpretable. They make it more controllable. This level of insight transforms research. It accelerates therapeutic development.
Tolemy Bio was founded in 2024. Alex Ward and Caelan Anderson launched the venture. Their vision is clear: build tools grounded in laboratory reality. This "scientists for scientists" approach is fundamental. It ensures Orbit meets real-world needs. The platform bridges biology, AI, software, and data infrastructure. This intersection is where scientific breakthroughs occur.
The pre-seed capital has specific deployment targets. A primary goal is to scale Orbit's capabilities. This includes expanding data generation. Machine learning resources will grow. Engineering capabilities will see significant investment. The company also plans to deepen customer relationships. Early customer and partner deployments will receive support. This ensures direct feedback and continuous improvement.
Team expansion is another crucial focus. Tolemy Bio actively recruits across disciplines. Scientific talent is sought. Technical experts are in high demand. This strategic growth strengthens the company's innovative core. It ensures Orbit's continued evolution. The team's expertise drives the virtual-cell intelligence layer.
Tolemy Bio operates globally. It is officially based in Cambridge, UK. However, significant deployment and operations occur in Barcelona, Spain. This dual presence leverages diverse talent pools. It embraces a broad scientific community. This global perspective enhances market reach.
A key partnership highlights Tolemy Bio's market strategy. The company collaborated with California-based GeminiBio. This partnership led to aiMOS. aiMOS is a model-driven offering. It supports custom supplement development for GeminiBio customers. This collaboration demonstrates Orbit's real-world applicability. It shows direct value in biopharma innovation.
The impact of such technology extends broadly. It promises to revolutionize drug discovery. It will accelerate the development of personalized medicines. Advanced therapies, particularly, stand to benefit. The ability to model and direct complex cellular systems is a game-changer. This marks a new era for biopharma.
AI's role in life sciences is expanding rapidly. Investments in companies like Tolemy Bio underscore this trend. The future of medicine involves increasingly sophisticated digital tools. Precision and control define this future. Orbit positions Tolemy Bio at the forefront of this transformation. The company offers a glimpse into tomorrow's advanced biomedical research. Its success will pave the way for numerous therapeutic advancements.